Chronic Obstructive Pulmonary Disease – Epidemiology – Middle East & Africa
DRG Epidemiology’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of COPD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.
DRG Epidemiology’s COPD forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with COPD?
In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of COPD?
Of all people with COPD, how many in each country have been formally diagnosed?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of COPD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following COPD subpopulations:
ACOS.
Eosinophilic COPD.
Severity status.
Drug-treatment status.
Exacerbations in mild-moderate disease status.
Exacerbations in severe-very severe disease status.
Chronic Obstructive Pulmonary Disease - Epidemiology - Middle East & Africa
Introduction
Key Findings
Total Prevalence: GOLD-Defined Chronic Obstructive Pulmonary Disease per 100 People Aged 40+ in 2018 and 2028
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases: GOLD-Defined Chronic Obstructive Pulmonary Disease over the Next Ten Years
Analysis of GOLD-Defined Prevalent Cases of Chronic Obstructive Pulmonary Disease in 2018 by Diagnosis Status
Analysis of the Total Prevalent Cases: GOLD-Defined Chronic Obstructive Pulmonary Disease in 2018 by Disease Severity
Epidemiology Data
Methods
Total incident cases: GOLD-defined
Total prevalent cases: GOLD-defined
Total GOLD-defined prevalent cases by severity
Diagnosed GOLD-defined prevalent cases
Lifetime DALYs gained
Reference Materials
Literature Review
Studies Included in the Analysis of Chronic Obstructive Pulmonary Disease
Studies Excluded from the Analysis of Chronic Obstructive Pulmonary Disease
Risk/Protective Factors
Risk/Protective Factors for Chronic Obstructive Pulmonary Disease
Bibliography
Stephanie Niquita
Stephanie Niquita Phankon, M.B.B.S., M.P.H.,is a senior epidemiologist at DRG, part of Clarivate. She trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects. She holds an M.P.H. specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China.
Abey John, M.P.H.
Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.
